Feb. 07, 2024 -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that its European Partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD) as the second indication in their license
Feb. 06, 2024 -- Linnea SA, a leading global Active Pharmaceutical Ingredients manufacturer with over 40 years of experience and a long-term presence in the Latam area, is pleased to announce the start of a strategic partnership with the Universidade Estadual de Campinas (UniCamp), a prestigious public research university in the state of São Paulo, Brazil. This important partnership aims to streamline and advance scientific development and research into cannabinoids.
The cannabinoid market in
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement with a well-tolerated safety profile in Phase 3 MANIFEST-2 study, when administered in combination with ruxolitinib in JAK inhibitor-naive MF patients1
Pelabresib and ruxolit
31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.
As previously announced, the transfer includes the entire Jyseleca® business, including the European and UK Marketing Authorizations, and the commercial, medical affairs and development activities for Jyseleca®. In connection with the completion of the transaction, approximately 400 Galapagos positions